Active Ingredient History

  • Now
Tezampanel is a drug originally developed by Eli Lilly which acts as a competitive antagonist of the AMPA and kainate subtypes of the ionotropic glutamate receptor family, with selectivity for the GluR5 subtype of the kainate receptor. It has neuroprotective and anticonvulsant properties, the former of which may, at least in part, occur via blockade of calcium uptake into neurons.   Wikipedia

  • SMILES: O.OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1
  • Mol. Mass: 297.36
  • ALogP: 0.61
  • ChEMBL Molecules:
More Chemistry
(3s,4ar,6r,8ar)-6-(2-(1(2)h-tetrazole-5yl)ethyl)decahydroisoquinoline-3carboxylic acid | 6-(2-(1h-tetrazol-5-yl)ethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid | ly 215490 | ly-215490 | ly293558 | ly 293558 | ly-293558 | ly 326325 | ly-326325 | ngx424 | tezampanel


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue